Jubilant Pharmova Dirección
Dirección controles de criterios 1/4
El CEO de Jubilant Pharmova's es Priyavrat Bhartia , nombrado en Jun 2023, tiene una permanencia de 1.17 años. compensación anual total es ₹67.47M, compuesta por 37.1% salario y 62.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.88% de las acciones de la empresa, por valor de ₹1.20B. La antigüedad media del equipo directivo y de la junta directiva es de 1.6 años y 6.5 años, respectivamente.
Información clave
Priyavrat Bhartia
Chief Executive Officer (CEO)
₹67.5m
Compensación total
| Porcentaje del salario del CEO | 37.1% |
| Permanencia del CEO | 1.3yrs |
| Participación del CEO | 0.9% |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 6.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 24
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%
Jan 11Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?
Dec 31Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares
Dec 20Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 08Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹67m | ₹25m | ₹771m |
Compensación vs. Mercado: La compensación total de Priyavrat($USD803.53K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD476.16K).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Priyavrat con los resultados de la empresa.
CEO
Priyavrat Bhartia (48 yo)
1.3yrs
Permanencia
₹67,466,997
Compensación
Mr. Priyavrat Bhartia, MBA, is the Non-Executive Chairman at Digicontent Limited and has been its Non-Executive Director since August 14, 2017. He has been Non-Executive Director of Hindustan Media Venture...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Director | 1.3yrs | ₹67.47m | 0.88% ₹ 1.6b | |
| Joint MD & Director | 1.3yrs | ₹67.47m | sin datos | |
| Group CFO & Whole-Time Director | 1.4yrs | ₹44.78m | sin datos | |
| Executive VP of Group Accounts | no data | sin datos | sin datos | |
| Group Chief Digital & Information Officer | no data | ₹16.53m | sin datos | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Executive VP & Head of Legal | 9.9yrs | ₹3.34m | sin datos | |
| Company Secretary & Compliance Officer | 2.2yrs | ₹6.86m | sin datos | |
| Group Chief Human Resources Officer | 1.8yrs | sin datos | sin datos | |
| Advisor | 4.6yrs | ₹67.29m | sin datos | |
| Senior Vice President of Corporate Affairs | no data | sin datos | sin datos | |
| President of Life Science Chemicals | no data | ₹19.34m | sin datos |
1.8yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de JUBLPHARMA no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Director | 7.4yrs | ₹67.47m | 0.88% ₹ 1.6b | |
| Joint MD & Director | 7.4yrs | ₹67.47m | sin datos | |
| Group CFO & Whole-Time Director | 3.5yrs | ₹44.78m | sin datos | |
| Additional Director & Whole-time Director | less than a year | sin datos | sin datos | |
| Chairman | 46.3yrs | sin datos | 0.085% ₹ 158.0m | |
| Independent Non-Executive Director | 7.4yrs | ₹2.59m | sin datos | |
| Independent Non-Executive Director | 6yrs | ₹2.01m | 0.0013% ₹ 2.3m | |
| Independent Director | less than a year | sin datos | sin datos | |
| Co-Chairman | 40.9yrs | ₹124.06m | 0.23% ₹ 436.9m | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | 7.4yrs | ₹2.53m | sin datos | |
| Additional Independent Non-Executive Director | 1.6yrs | ₹2.23m | sin datos |
6.7yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de JUBLPHARMA se considera experimentada (6.4 años de antigüedad promedio).